Seattle, WANCT07335523Now EnrollingIRB Ready

Exocrine Pancreatic Insuficiency Clinical Trial in Seattle, WA

Access cutting-edge exocrine pancreatic insuficiency treatment through this clinical trial at a research site in Seattle. Study-provided care at no cost to qualified participants.

Sponsored by Digestive Care, Inc.

Quick Self-Assessment

See if you qualify for this Seattle location

Preparing your pre-screening questions…

Expert Care in Seattle

Access exocrine pancreatic insuficiency specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related exocrine pancreatic insuficiency treatment provided free

Apply for This Seattle Location

Check if you qualify for this exocrine pancreatic insuficiency clinical trial in Seattle, WA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Seattle

    Convenient for WA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Seattle site if eligible
  4. 4Begin participation

About This Exocrine Pancreatic Insuficiency Study in Seattle

The goal of this clinical trial is to determine the prevalence of exocrine pancreatic insufficiency (EPI) in a population of pediatric and adult participants with Alagille Syndrome (ALGS) post liver transplant. During the study, participants will: * Consume a high fat diet * Keep a diary of their abdominal signs and symptoms, and stool frequency and consistency * Collect stool for laboratory testing

Sponsor: Digestive Care, Inc.

Who Can Participate

Inclusion Criteria

Male and female participants ages 7-50 years inclusive.
Confirmed diagnosis of ALGS
Status post OLT due to ALGS complications.
Participants currently managed with pancreatic enzyme products (PEPs) are allowed pending discontinuation of PEPs for 5 days prior to beginning the 72-hour stool collections. Participants must discontinue PEPs for the entire study period until completion.
Agree to adhere to a high fat diet at least 2 days prior to and during the 72-hour stool collections and monitor dietary consumption through the use of a diet diary.
Have a consistent caregiver for the duration of the study if applicable for enrollment of a child.
Capable of giving written informed consent and assent (if age appropriate).

Exclusion Criteria

Surgical disruption of the enterohepatic circulation (e.g., biliary diversion).
Subjects with alternative etiologies of EPI (e.g., chronic panreatitis, pancreatic resection).
Diets high in medium-chain triglyceride (MCT) oil.
Use of bile acids, bile acid uptake inhibitors, lipid-binding resins, synthetic fat substitutes (e.g. Olestra), and diaper rash ointments (note that H2 antagonists and proton pump inhibitors \[PPIs\] are permitted if on a stable and consistent regimen throughout the duration of the study).
History or presence of other concomitant liver diseases such as liver transplant rejection with cholestasis, hepatitis B or C virus infection, HIV, primary sclerosing cholangitis (PSC), alcoholic liver disease, autoimmune hepatitis, metabolic-associated fatty liver disease (MASLD)/non-alcoholic steatohepatitis (NASH) or significant chronic allograft rejection.
Currently pregnant or breastfeeding.
Cancers except for in situ carcinoma or cancers treated at least 5 years prior to screening with no evidence of recurrence.
Participation in a clinical trial and received an investigational product within the last 30 days.
Use of anti-diarrheal, anti-spasmodic, and/or cathartic laxatives. Change in osmotic laxatives within the past 3 months.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Seattle?

Yes, this clinical trial (NCT07335523) has an active research site in Seattle, WA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Exocrine Pancreatic Insuficiency Treatment Options in Seattle, WA

If you're searching for exocrine pancreatic insuficiency treatment options in Seattle, WA, this clinical trial (NCT07335523) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Seattle research site is actively enrolling participants for this clinical trial. You'll receive care from experienced exocrine pancreatic insuficiency specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all exocrine pancreatic insuficiency clinical trials near you to find additional studies recruiting in your area.

More Interstitial Cystitis Trials in Seattle, WA

See all interstitial cystitis clinical trials recruiting in Seattle — not just this study.

Browse Interstitial Cystitis Trials in Seattle →

Browse More Trials by Condition

Interstitial Cystitis TrialsAll Conditions →

Ready to Join in Seattle?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Seattle, WA